The potential for the development of therapeutic oligonucleotides into clinical medicines and their use as basic research tools are explored in this volume, which is the proceedings of the 7th NIH Symposium on Therapeutic Oligonucleotides. The focus is on antisense, RNAi, triple-helix, gene repair, DNA chips, and CpG immune modulatory oligonucleotides. Specific chapters address designing better siRNAs, splice switching oligonucleotides, selective delivery of oligonucleotides, and medicinal drugs by receptor-mediated endocytosis, development of a function overriding siRNA silencing in mammalian…mehr
The potential for the development of therapeutic oligonucleotides into clinical medicines and their use as basic research tools are explored in this volume, which is the proceedings of the 7th NIH Symposium on Therapeutic Oligonucleotides. The focus is on antisense, RNAi, triple-helix, gene repair, DNA chips, and CpG immune modulatory oligonucleotides. Specific chapters address designing better siRNAs, splice switching oligonucleotides, selective delivery of oligonucleotides, and medicinal drugs by receptor-mediated endocytosis, development of a function overriding siRNA silencing in mammalian cells, transcription factor decoys, and modified oligonucleotide hybridization and genetic insertion. NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas. ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit www.nyas.org/membership/main.asp for more information about becoming a member.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Yoon S. Cho-Chung and Alan M. Gewirtz are the authors of Therapeutic Oligonucleotides: Transcriptional and Translational Strategies for Silencing Gene Expression, Volume 1058, published by Wiley.
Inhaltsangabe
Introduction: Y S Cho-Chung Alan M. Gewirtz and Cy A. Stein. Part I: Kill the Messenger: Gene Silencing by Nucleic Acid Molecules. 1. Knock-down of the Cytoprotective Gene Clusterin to Enhance Hormone and Chemosensitivity in Prostate and Other Cancers: Martin Gleave and Kim N. Chi. 2. Recognition of Chromosomal DNA in Human Cells by Peptide Nucleic Acids and Small Duplex RNAs: David R. Corey. Part II: Antisense and siRNA: Chemistry Sequence Specificity and Target Validation. 3. Design and Development of Thermolytic DNA Oligonucleotide Prodrugs: Andrzej Grajkowski Joao Pedras-Vasconcelos Cristina Ausín Daniela Verthelyi and Serge L. Beaucage. 4. Rationally Targeted Conformationally Constrained Oxetane-Modified Oligonucleotides Demonstrate Efficient Gene-Silencing Activity in a Cellular System: J B Opalinska and A M Gewirtz. Part III: Delivery Cellular and Phenotype Effect of Silencing Agents:. 5. In Vivo Potentialities Andrei Maksimenko Valerie Polard Marie Villemeur Hind Elhamess Patrick Couvreur Jean-Remi Bertrand Malam Aboubakar Marina Gottikh and Claude Malvy of EWS-Fli-1 Targeted Antisense Oligonucleotides-Nanospheres Complexes:. 6. Endo-Porter: A Novel Reagent for Safe Effective Delivery of Substances into Cells: James E. Summerton. 7. Tumor Reversion: Protein Kinase A Isozyme Switching: Yoon S. Cho-Chung and Maria V. Nesterova. Part IV: Immune Modulation of and Resistance to Silencing Agents. 8. Therapeutic Potential of Oligonucleotides Expressing Immunosuppressive TTAGGG Motifs: Dennis M. Klinman Ihsan Gursel Sven Klaschik Li Dong Debbie Currie and Hidekazu Shirota. 9. Breaking Tolerance to Tumors with Dendritic Cell-Based Immunotherapy: Ines Mende and Edgar G. Engleman. 10. Development of Resistance to RNAi in Mammalian Cells: Zhi-Ming Zheng Shuang Tang and Mingfang Tao. Part V: Transcription Silencing by Nucleic Acid Molecules. 11. The Development of Bioactive Triple Helix-Forming Oligonucleotides: Michael M. Seidman Nitin Puri Alokes Majumdar Bernard Cuenoud Paul S. Miller and Rowshon Alam. 12. Transcription Factor Decoys: A New Model for Disease Intervention: Michael J. Mann. 13. DNA Damage Produced by 125I-Triplex-Forming Oligonucleotides as a Measure of Their Succesful Delivery into Cell Nuclei: Irina V. Panyutin Olga A. Sedelnikova William M. Bonner Igor G. Panyutin and Ronald D. Neumann. 14. Targeted Genome Modification via Triple Helix Formation: Jennifer M. Kalish and Peter M. Glazer. Part VI: Functional Genomics-Antisense/RNAi. 15. "Promoter Array" Studies Identify Cohorts of Genes Directly Regulated by Methylation Copy Number Change or Transcription Factor Binding in Human Cancer Cells: Yipeng Wang Jun Hayakawa Fred Long Qiuju Yu Ann H. Cho Gaelle Rondeau John Welsh Shalu Mittal Ian De Belle Eileen Adamson Michael Mcclelland and Dan Mercola. 16. Application of Expression Genomics for Predicting Treatment Response in Cancer: Khew-Voon Chin Leah Alabanza Kazuyuki Fujii Kazuya Kudoh Tsunekazu Kita Yoshihiro Kikuchi Zachariah E. Selvanayagam Yick Fu Wong Yong Lin and Wei Chung Shih. 17. Stability Regulation of mRNA and the Control of Gene Expression: Chris Cheadle Jinshui Fan Yoon S. Cho-Chung Thomas Werner Jill Ray Lana Do Myriam Gorospe and Kevin G. Becker. Part VII: Chemosensitivity Enhancement by Antisense and RNAi. 18. Novel MDM2 p53-Independent Functions Identified through RNA Silencing Technologies: Zhuo Zhang Hui Wang Mao Li Elizabeth Rayburn Sudhir Agrawal and Ruiwen Zhang. 19. Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/ GEM®640: Eric C. Lacasse Ekambar R. Kandimalla Peter Winocour Tim Sullivan Sudhir Agrawal John W. Gillard and Jon Durkin. Part VIII: Nucleic Acid Therapeutics for Human Diseases. 20. Induction of Apoptosis by G3139 in Melanoma Cells: Luba Benimetskaya Johnathan C. Lai Anastasia Khvorova Sijian Wu Paul Miller and C A Stein. 21. Zebularine: A Unique Molecule for an Epigenetically Based Strategy in Cancer Chemotherapy: Victor E. Marquez James A. Kelley Riad Agbaria Tisipi Ben-Kasus Jonathan C. Cheng Christine B. Yoo and Peter A. Jones. 22. Chemoprevention with Protein Kinase A RI Antisense in DMBA-Mammary Carcinogenesis: Maria V. Nesterova and Yoon S. Cho-Chung
Introduction: Y S Cho-Chung Alan M. Gewirtz and Cy A. Stein. Part I: Kill the Messenger: Gene Silencing by Nucleic Acid Molecules. 1. Knock-down of the Cytoprotective Gene Clusterin to Enhance Hormone and Chemosensitivity in Prostate and Other Cancers: Martin Gleave and Kim N. Chi. 2. Recognition of Chromosomal DNA in Human Cells by Peptide Nucleic Acids and Small Duplex RNAs: David R. Corey. Part II: Antisense and siRNA: Chemistry Sequence Specificity and Target Validation. 3. Design and Development of Thermolytic DNA Oligonucleotide Prodrugs: Andrzej Grajkowski Joao Pedras-Vasconcelos Cristina Ausín Daniela Verthelyi and Serge L. Beaucage. 4. Rationally Targeted Conformationally Constrained Oxetane-Modified Oligonucleotides Demonstrate Efficient Gene-Silencing Activity in a Cellular System: J B Opalinska and A M Gewirtz. Part III: Delivery Cellular and Phenotype Effect of Silencing Agents:. 5. In Vivo Potentialities Andrei Maksimenko Valerie Polard Marie Villemeur Hind Elhamess Patrick Couvreur Jean-Remi Bertrand Malam Aboubakar Marina Gottikh and Claude Malvy of EWS-Fli-1 Targeted Antisense Oligonucleotides-Nanospheres Complexes:. 6. Endo-Porter: A Novel Reagent for Safe Effective Delivery of Substances into Cells: James E. Summerton. 7. Tumor Reversion: Protein Kinase A Isozyme Switching: Yoon S. Cho-Chung and Maria V. Nesterova. Part IV: Immune Modulation of and Resistance to Silencing Agents. 8. Therapeutic Potential of Oligonucleotides Expressing Immunosuppressive TTAGGG Motifs: Dennis M. Klinman Ihsan Gursel Sven Klaschik Li Dong Debbie Currie and Hidekazu Shirota. 9. Breaking Tolerance to Tumors with Dendritic Cell-Based Immunotherapy: Ines Mende and Edgar G. Engleman. 10. Development of Resistance to RNAi in Mammalian Cells: Zhi-Ming Zheng Shuang Tang and Mingfang Tao. Part V: Transcription Silencing by Nucleic Acid Molecules. 11. The Development of Bioactive Triple Helix-Forming Oligonucleotides: Michael M. Seidman Nitin Puri Alokes Majumdar Bernard Cuenoud Paul S. Miller and Rowshon Alam. 12. Transcription Factor Decoys: A New Model for Disease Intervention: Michael J. Mann. 13. DNA Damage Produced by 125I-Triplex-Forming Oligonucleotides as a Measure of Their Succesful Delivery into Cell Nuclei: Irina V. Panyutin Olga A. Sedelnikova William M. Bonner Igor G. Panyutin and Ronald D. Neumann. 14. Targeted Genome Modification via Triple Helix Formation: Jennifer M. Kalish and Peter M. Glazer. Part VI: Functional Genomics-Antisense/RNAi. 15. "Promoter Array" Studies Identify Cohorts of Genes Directly Regulated by Methylation Copy Number Change or Transcription Factor Binding in Human Cancer Cells: Yipeng Wang Jun Hayakawa Fred Long Qiuju Yu Ann H. Cho Gaelle Rondeau John Welsh Shalu Mittal Ian De Belle Eileen Adamson Michael Mcclelland and Dan Mercola. 16. Application of Expression Genomics for Predicting Treatment Response in Cancer: Khew-Voon Chin Leah Alabanza Kazuyuki Fujii Kazuya Kudoh Tsunekazu Kita Yoshihiro Kikuchi Zachariah E. Selvanayagam Yick Fu Wong Yong Lin and Wei Chung Shih. 17. Stability Regulation of mRNA and the Control of Gene Expression: Chris Cheadle Jinshui Fan Yoon S. Cho-Chung Thomas Werner Jill Ray Lana Do Myriam Gorospe and Kevin G. Becker. Part VII: Chemosensitivity Enhancement by Antisense and RNAi. 18. Novel MDM2 p53-Independent Functions Identified through RNA Silencing Technologies: Zhuo Zhang Hui Wang Mao Li Elizabeth Rayburn Sudhir Agrawal and Ruiwen Zhang. 19. Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/ GEM®640: Eric C. Lacasse Ekambar R. Kandimalla Peter Winocour Tim Sullivan Sudhir Agrawal John W. Gillard and Jon Durkin. Part VIII: Nucleic Acid Therapeutics for Human Diseases. 20. Induction of Apoptosis by G3139 in Melanoma Cells: Luba Benimetskaya Johnathan C. Lai Anastasia Khvorova Sijian Wu Paul Miller and C A Stein. 21. Zebularine: A Unique Molecule for an Epigenetically Based Strategy in Cancer Chemotherapy: Victor E. Marquez James A. Kelley Riad Agbaria Tisipi Ben-Kasus Jonathan C. Cheng Christine B. Yoo and Peter A. Jones. 22. Chemoprevention with Protein Kinase A RI Antisense in DMBA-Mammary Carcinogenesis: Maria V. Nesterova and Yoon S. Cho-Chung
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
